10 recruiting, 5 active not recruiting, 4 completed, 1 not yet recruiting. 22 Phase 1, 10 Phase 2.
Follow Pluvicto: new trials by email Literature Review of Pluvicto trials Research Report on Pluvicto
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-12-01 | 2026-10-15 |
| 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE) - Metastatic Prostate Cancer, Prostate Cancer | Phase 1 | Recruiting | University of California, San Francisco | 30 | 2026-03-16 | 2026-06-01 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC AMO959, AAA617, Enzalutamide - PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 123 | 2025-12-05 | 2026-10-15 |
| A Study of 177Lu-PSMA-617 in People With Gliomas Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI - Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2025-10-27 | 2026-06-04 |
| Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) 177Lu-PSMA-617 - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Jean-Mathieu Beauregard | 60 | 2025-08-15 | 2025-09-09 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy - Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Thomas Hope | 45 | 2025-07-08 | 2026-08-28 |
| STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT) - Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Angela Y. Jia, MD PhD | 45 | 2025-05-13 | 2026-05-26 |
| 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Baptist Health South Florida | 2024-10-01 | 2024-09-19 | |
| LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer Carboplatin, 177Lu-PSMA-617 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 37 | 2024-05-22 | 2026-04-08 |
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 148 | 2023-12-11 | 2026-05-22 |
| Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer Cabozantinib - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | University of Utah | 33 | 2023-07-14 | 2026-08-12 |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer Cabazitaxel, 177Lu-PSMA-617 - Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 35 | 2022-07-14 | 2025-04-06 |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Abemaciclib, Lutetium Lu 177-PSMA-617 - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Vadim S Koshkin | 30 | 2022-07-08 | 2026-07-24 |
| EBRT + Lu-PSMA for N1M0 Prostate Cancer 177Lu-PSMA-617, EBRT - Prostatic Neoplasm | Phase 1 | Completed | The Netherlands Cancer Institute | 14 | 2021-12-20 | 2025-12-10 |
| A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer 177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT) - Prostate Cancer | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 29 | 2021-10-01 | 2026-06-25 |
| Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11 - Prostate Cancer | Phase 1 | Recruiting | Weill Medical College of Cornell University | 42 | 2021-06-30 | 2026-06-11 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer Lu-177 PSMA-617 - Prostate Neoplasm | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 10 | 2018-07-01 | 2019-11-14 |
Showing 20 of 22. Sign in to see all of them.
Prostatic Neoplasms (16) · Astrocytoma (1) · Disease (1) · Glioblastoma (1) · Glioma (1)
Weill Medical College of Cornell University (3) · Memorial Sloan Kettering Cancer Center (2) · Peter MacCallum Cancer Centre, Australia (2) · University of California, San Francisco (2) · Angela Y. Jia, MD PhD (1) · Baptist Health South Florida (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Jean-Mathieu Beauregard (1) · Novartis Pharmaceuticals (1) · OncoC4, Inc. (1) · Radboud University Medical Center (1) · The Netherlands Cancer Institute (1) · Thomas Hope (1) · University of Michigan Rogel Cancer Center (1)
United States (17) · Australia (3) · Netherlands (2) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1)
Brandon Imber, MD (2) · Rahul Aggarwal, MD (2) · Scott Tagawa, MD (2) · Alex Chehrazi-Raffle, MD (1) · Angela Y Jia, MD, PhD (1) · Daniel E Spratt, MD (1) · David Wise, MD (1) · Declan Murphy (1) · James Nagarajah, Prof. (1) · Jean-Mathieu Beauregard, MD (1) · John Violet (1) · Joseph Osborne, MD (1) · Kirk A Frey, MD (1) · Mark Stein, MD (1)
PMID 33465252, PMID 33883176, PMID 36692682, PMID 36959540, PMID 37891072, PMID 37922930, PMID 39978808
2025 (1), P30CA033572 (1), R01CA229354 (1), R01CA289631 (1)